Why Investors are Wrong about Gilead

Big biotech Gilead (Nasdaq: GILD) has gone on a tremendous 200% two year run as its groundbreaking hepatitis-C cure Sovaldi is breaking all expectations with $2.3 billion in just its first quarter of availability.

This has led to nothing but praise for the big biotech and investors are riding high. But are they missing warning signs that all is not well with Gilead.

In this episode of Market Check-Up, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass, play a game of bull vs bear. Michael takes the banner for pro-Gilead crowd while David tries to bunch holes in his bullish argument.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


The article Why Investors are Wrong about Gilead originally appeared on Fool.com.

David Williamson owns shares of AbbVie. and Merck. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story